Bibliography:


Son, S., Ma, J., Kondou, Y., Yoshimara, M., Yamashita, E. & Tshukihara, T. 2008. Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for


Acknowledgements:

- My Heavenly Father for giving me the talents and opportunities to make this study possible.
- My supervisor, Prof. J.P. Petzer for all his patience, planning, assistance and support with this study.
- My co-supervisor, Dr. A. Petzer for all her assistance with the enzymology.
- My parents- Kallie and Annemarie- and family – Fanie, Finney and Esté- for believing in me and all their support.
- All my friends for their encouragement and support.
- The North-West University for providing the facilities and financial support that made this study possible.
- This work is based on the research supported in part by the Medical Research Council and National Research Foundation of South Africa [Grant specific reference numbers (UID) 85642 and 80647]. The Grantholders acknowledge that opinions, findings and conclusions or recommendations expressed in any publication generated by the NRF supported research are that of the authors and that the NRF accepts no liability whatsoever in this regard.
Annexure A – Letter of permission

Ms. M. Barkhuizen
1 November 2013

To whom it may concern:

Dear Sir / Madam

CO-AUTHORSHIP ON RESEARCH PAPERS

The undersigned, as co-authors of the research article listed below, hereby give permission to Ms. Melinda Barkhuizen to submit the paper as part of the degree M.Sc. in Pharmaceutical Chemistry at the North-West University, Potchefstroom Campus.

I. The inhibition of monoamine oxidase by phenformin and pentamidine.

Yours sincerely,

_________________________          __________________________
Prof. J.P. Petzer                       Dr. A. Petzer
Annexure B – Author instructions and letter of permission to use article.

Arzneimittelforschung/ Drug Research

Information for Authors

Arzneimittelforschung/Drug Research accepts manuscripts in English covering drug research and development as well as the latest scientific findings on substances and/or products already marketed. The journal accepts manuscripts from the following areas: analytics, bioavailability, biochemistry, bioequivalence, chemistry, clinical pharmacology, drug interactions, efficacy testing, experimental pharmacology, pharmacodynamics, pharmacokinetics, teratology, toxicity as well as questions related to drug formulation, mathematical and statistical methods for the evaluation of results from industrial investigations as well as clinical trials. Translational medicine aspects are key features of the journal.

When submitted, manuscripts must not have been published elsewhere or be under simultaneous consideration by another journal. The aim of the journal is to disseminate new and reliable experimental data from the field of drug research to scientists and doctors worldwide.

N.B.: Incorrect English can result in the immediate rejection of your manuscript whereas correct English will help a speedy publication process. It is in your own interest to ensure that your paper has been read by a native speaker of English; alternatively, you should use a copy-editing service like “American Journal Experts” if you have concerns about the English in your manuscript.

These types of manuscripts will be accepted:

- Original Articles
- Reviews
- Commentaries
- Controversies
- Opinion Papers
- Short Communications
- Letters

Clinical Trials

The Journal supports trial registration. All trials reported must be registered at an official registry recognised by the International Committee of Medical Journal Editors, such as ClinicalTrials.gov (www.clinicaltrials.gov) or any of the primary registries on the World Health Organization’s International Clinical Trial Registry Platform (www.who.int/ictrp).

Conflict of Interest

Please state the conflicts of interest of all authors. During the online submission process, you will be asked to declare your conflicts of interest. Failure to do so or an incomplete declaration may result in non-publication.

Ethics

The journal is very concerned about ethical standards. Please provide proof that the terms of the latest version of the “World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects” have been adhered to or provide approval of your local ethics committee. The same applies to animals. Please provide proof that experiments involving animals were carried out in compliance with the “Guide for the Care and Use of Laboratory animals” published by the National Academy of Sciences or else provide approval of your local ethics committee.

Manuscript Submission

All manuscripts must be submitted exclusively via online submission at http://mc.manuscriptcentral.com/aml

Submissions of hardcopy manuscripts will not be accepted. Please include tables and figures as separate files, they should not be integrated into the main document, but a list with the legends of the figures and tables should be included there. Provide graphic files with sufficient resolution: coloured and black-white bitmaps: 300 dpi; diagrams and line drawings: 600 dpi minimum. Figures should be serially numbered with Arabic numerals. There should be a clear mark in the manuscript indicating where the figure should be inserted.

Authors are responsible for the correctness of the manuscripts and the list of references. All measurements must be in Systeme International (SI) units.

A. Original Articles

Original papers should deal with investigations and results of high scientific value which have not been published previously.

1. Original papers should not exceed 6 printed pages, i.e. 15 type-written double-spread manuscript pages of 30 lines of 60 letters each, including references, tables, figures and legends. Please do not use more than one blank space between words and sentences.

2. Preparation of manuscripts

Authors are asked to follow the outline set below:

Page 1: a) title, b) short running title (limit: 40 characters), c) name of the author(s) (no titles or academic grades) and address of the institute(s) where the investigations have been carried out. Should the address of the author at the time of publication differ from the one stated in the paper, the current address should be stated in a footnote, d) complete mailing address of corresponding author including telephone and fax numbers and e-mail addresses.

Page 2: a) a structured abstract containing no more than 250 words with no abbreviations, b) keywords (3–6 without repeating words in the title).

Page 3 and onwards: a) introduction also indicating the aim of the study, b) materials and methods, c) results: double presentation of data in the form of text, tables or figures should be avoided, d) discussion and conclusions, e) list of references, f) legends of tables and figures. Do include your acknowledgement in the main document.

3. References

a) Text: Citations and references should be numbered consecutively using square brackets in the order in which they are cited in the text, followed by any in tables or legends. Please do not number references under alphabetical order of authors. Do not use footnotes and hyperlinks. If authors are mentioned in the text, only the first author should be given followed by “et al.” whenever the reference has three or more authors. Example: “…protein concentrations were determined according to Lowry et al. [1].”

b) List of References: References should be given as plain text. Do not use fields in MS Word, as these are difficult to process later. The references should be listed in numbered order according to the sequence they appear in the text. Preferably, all authors or groups of authors of each publication should be mentioned. The name of the author(s) should be followed by the full title of the paper, name of the journal in which it has been published (abbreviations according to “Index Medicus”), year of publication, volume, first and last page. Abstracts and supplements have to be indicated. Chapters from books have to be cited as follows: author(s), title of chapter, title of book, editor(s), place of publication, publisher, year of publication, first and last page of the chapter. See also the recommendations of the International Committee of Medical Journal Editors (www.icmje.org).

Examples:


B. Reviews

Reviews deal with previous research on a certain topic and serve to summarize current findings on the topic so far. The structure of the review will vary from an original paper according to the nature of the review, but please adhere to the guidelines concerning refer-
ences. Please aim at no more than 20 type-written pages and 100 references.

C. Commentaries
They usually follow the article that they discuss, have no special structure and are usually invited. They could also deal with an actual topic such as pivotal new scientific findings in the field. Commentaries should not exceed 6 type-written pages, with a maximum of 20 references. Please adhere to the reference guidelines outlined above.

D. Opinion Papers, Controversies
The structure of these papers will vary from an original paper according to the nature of the topic and argument. Opinion papers present the authors’ comprehensive views on current developments in the area and discuss perspectives for the future. Controversies describe a relevant ongoing scientific dispute from an unbiased point of view. They should not exceed 10 type-written pages, with a maximum of 40 references. Please adhere to the guidelines concerning references outlined above.

E. Short Communications
Short Communications are completed projects of smaller scope and should contain new clinical and experimental data of immediate interest.
1. They should not exceed 2 printed pages (i.e. 6 type-written double-spaced pages in manuscript 30 lines of 60 letters each) and may include 1 table and 1 figure. The list of references at the end of the paper should not exceed 10 citations.
2. The guidelines for the structure of Short Communications are the same as for Original Articles with the following exceptions: a) no keywords and b) no titles of the papers in the list of references.

F. Letters
This section has been introduced to encourage authors to engage in a free exchange of ideas. The opinions presented do not necessarily reflect the opinions of the Editors.

Page Charges
The publisher will impose a page charge of 160 € per printed page (including 19% VAT) starting with the seventh page.

Reproduction of Color Figures
The journal’s fee for color reproduction amounts to € 440 for the first color figure and € 80 for any further figure (including 19% VAT).

Proofs and Reprints as PDF File
Galley proofs will be sent to the corresponding author as a PDF file. At this stage of the production process, only minor corrections (typos, obvious errors in the production process) are accepted. All other alterations will trigger a de-novo submission. The corresponding author receives a PDF file of the published article free of charge.

Copyright
The publisher holds the copyright to all material appearing in the journal. A Copyright Transfer Agreement will be sent to the corresponding author together with the galley proofs. The agreement must be completed and returned to the publishers before the article can be published. If material taken from foreign sources (including figures, etc.) is included in a manuscript submitted to the journal it must be indicated as such by citation of the original source and, whenever necessary, permission for reproduction must be obtained from the respective publishing company.

Editor-in-Chief:
Martin Wehling, MD
Professor of Medicine
Institute of Experimental and Clinical Pharmacology and Toxicology
Medical Faculty Mannheim
University of Heidelberg
Maybachstr. 14
68169 Mannheim
Germany
E-mail: arzneimittelforschung@thieme.de
Letter of permission to use article:
Von: Melinda Barkhuizen [mailto:21686866@nwu.ac.za]
Gesendet: Monday, November 25, 2013 2:24 PM
An: Wenzel, Dr. Regina
Betreff: Permission to use article for scholarly purposes

GEORG THIEME VERLAG
Scientific Publications Division

Dear Dr. Wentzel


With this letter, I ask permission to use the above manuscript for scholarly purposes, specifically to incorporate unedited (by Georg Thieme Verlag) versions of the article into the dissertation for my Masters degree. Hard copies of my dissertation will be kept in the libraries of the North-West University. In addition my study leader and the examiners of the dissertations will each obtain a copy of the dissertations.

Thank you,

Melinda Barkhuizen
Dept. of Pharmaceutical Chemistry
North-West University
Private bag X6001
Potchefstroom, 2520, South Africa
Tel. 018-299 2206
Fax 018 299 4243
Dear Ms Barkhuizen,

We herewith grant you permission to use the final manuscript version of the article mentioned below for incorporation into your Master’s thesis. Please note that the permission covers only this use, should you wish to use the article for further/other purposes, please contact me again.

Thank you and very best regards,

Regina Wenzel

Dr. Regina Wenzel
Programmplanung / Publishing Editor
Georg Thieme Verlag KG
Rüdigerstraße 14  |  70469 Stuttgart
Fon +49 711/8931-102
Fax +49 711/8931-392
regina.wenzel@thieme.de
www.thieme.de

Georg Thieme Verlag KG  |  Rüdigerstr. 14  |  70469 Stuttgart
Rechtsform: KG  |  Sitz und Handelsregister: Stuttgart, HRA 3499
## Annexure C – Contributions of authors

<table>
<thead>
<tr>
<th>Author</th>
<th>Contributions</th>
<th>Consent*</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Barkhuizen</td>
<td>Responsible for planning the study and carrying out the modelling and enzymology. Writing of the dissertation and articles.</td>
<td></td>
</tr>
<tr>
<td>Prof. J.P. Petzer</td>
<td>Design of the project.</td>
<td></td>
</tr>
<tr>
<td>Dr. A. Petzer</td>
<td>Assistance with the enzymology.</td>
<td></td>
</tr>
</tbody>
</table>

*I declare that I have approved the article and that my role in the study was as indicated above. I hereby give my consent that the article may be published as part of the dissertation of M. Barkhuizen.*

186